The British Pharmacological Society and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists published a joint statement in the British Journal of Clinical Pharmacol...
News & Events
Webinar on June 18th: HIV Deja Vu? Optimizing combination therapies for COVID-19
With a vaccine likely a year or longer away, there is urgency around determining the right therapeutic at the right dose to fight COVID-19. Results from clinical trials of monotherapies have been a mi...
Perspectives on CPT: A Real‐World Evidence Framework for Optimising Dosing in All Patients with COVID‐19
A COVID-19 call to action in Clinical Pharmacology & Therapeutics from Richard Peck, Daniel Weiner, Jack Cook and Bob Powell. “The Global Heads of Clinical Pharmacology from the pharmaceutic...
Commentary on CTS: Time for the global pharmacology community to step up
In this commentary in Clinical and Translational Science, the authors urge the global translational and quantitative pharmacology community to come together and contribute our tools and know-how to fi...
Webinar on May 14: Model-informed Drug Repurposing – Applications for COVID-19
The global scientific community’s scramble to rapidly find therapeutics for COVID-19 has been reassuring, but unfortunately also chaotic. There are now almost 700 clinical trials conducted, planned ...
Webinar: New Opportunities & Implications for the Future of Drug Development in Emerging Economies
The COVID-19 epidemic has led to new sources of research funding being channeled towards emerging economies. This funding from philanthropists and global governance bodies reflects the fact that emerg...
COVID-19 drug development in the critically ill – a “special population”
Commentary by Carl Kirkpatrick, PhD. Professor at Monash University As the number of patients diagnosed with COVID-19 exceeded the 2.5 million worldwide, the impact on the hospital systems in many cou...
Dosing is critical in repurposing antivirals for COVID‐19
Commentary by Dr. Patrick Smith With no approved treatments for COVID-19, repurposing existing drugs is an attractive option. But, getting the dose right is more complicated than it might seem. Here...
Ivermectin is unlikely to be clinically effective for COVID-19.
Commentary by Dr. Craig Rayner and Dr. Karen Yeo Recently in Antiviral research, Caly et al.(1) reported the in vitro activity of ivermectin against SARS-CoV-2 in SERO cells. The study, described th...
April 23rd Virtual Panel Discussion: COVID-19: Trials, Designs and Tools for Promising Results
In response to the COVID-19 pandemic, there are over 500 global clinical trials taking place to develop life-saving treatments and vaccines for patients. In these unprecedented times, sponsors must ut...